Literature DB >> 20046331

Dexamethasone and antibiotics for the empirical treatment of bacterial meningitis in Canadian children: A survey of paediatric infectious diseases specialists.

Bjk Tan1, Hd Davies.   

Abstract

PURPOSE: With the changing epidemiology of the etiological agents causing bacterial meningitis in Canada, the purposes of this study were to determine what empirical antibiotic(s) is/are advocated, and whether dexamethasone is recommended as adjunctive therapy by paediatric infectious diseases specialists for suspected meningitis caused by Streptococcus pneumoniae, Neisseria meningitides, Haemophilus influenzae type b, and partially treated (PT) bacterial meningitis.
METHODS: A questionnaire invoking the specialists' preferred choices in treating bacterial meningitis was circulated by e-mail in March 1999 to 41 paediatric infectious diseases specialists or microbiologists (Paediatric Investigators Collaborative Network on Infections in Canada [PICNIC] members) who practised in 13 paediatric centres located in eight provinces.
RESULTS: Thirty-two (78% response rate) replies were received by July 1999 from 11 paediatric centres in seven provinces. Dexamethasone was recommended by 11 of 32 (34%) respondents for suspected S pneumoniae, four of 32 (12%) for suspected N meningitides, 18 of 32 (56%) for suspected H influenzae type b and five of 32 (16%) for suspected PT meningitis. A trend for more frequent recommended use of dexamethasone for S pneumoniae, H influenzae type b and N meningitides meningitis was found in eastern provinces (Ontario, Quebec and Nova Scotia), as opposed to the western provinces (Manitoba, Saskatchewan, Alberta and British Columbia). The most commonly recommended first line empirical antibiotic therapy was vancomycin plus 3rd-generation cephalosporin (V+3C). This was recommended by 27 of 32 (84%) respondents for suspected S pneumoniae, seven of 32 (22%) for suspected N meningitides, six of 32 (19%) for suspected H influenzae type b and 24 of 32 (75%) for PT meningitis; the remainder recommended using a 3C empirically for each type of meningitis. The major reason cited by respondents for using V+3C for suspected S pneumoniae was the presence of high-and intermediate-level penicillin-resistant S pneumoniae in their centres. No differences were found in the choice of antibiotic(s) between practitioners in the eastern and western provinces.
CONCLUSIONS: Although regional differences exist, the majority of paediatric infectious diseases experts no longer favour the use of dexamethasone for empirical therapy in most cases of bacterial meningitis. V+3C has become the regimen of choice in Canada for most cases of suspected bacterial meningitis.

Entities:  

Keywords:  Antibiotic therapy; Bacterial meningitis; Dexamethasone

Year:  2002        PMID: 20046331      PMCID: PMC2795687     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  25 in total

1.  An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2002-01-15

2.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC): the politics and positives of a cooperative study group for the PICNIC.

Authors:  E E Wang; D Scheifele; B J Law; N E MacDonald
Journal:  J Clin Epidemiol       Date:  1997-04       Impact factor: 6.437

Review 3.  Treatment of bacterial meningitis.

Authors:  V J Quagliarello; W M Scheld
Journal:  N Engl J Med       Date:  1997-03-06       Impact factor: 91.245

4.  Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988.

Authors:  P B McIntyre; C S Berkey; S M King; U B Schaad; T Kilpi; G Y Kanra; C M Perez
Journal:  JAMA       Date:  1997-09-17       Impact factor: 56.272

5.  Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.

Authors:  I R Friedland; S Shelton; M Paris; S Rinderknecht; S Ehrett; K Krisher; G H McCracken
Journal:  Pediatr Infect Dis J       Date:  1993-03       Impact factor: 2.129

6.  Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada.

Authors:  J D Wenger
Journal:  Pediatr Infect Dis J       Date:  1998-09       Impact factor: 2.129

7.  Therapy of bacterial sepsis, meningitis and otitis media in infants and children: 1992 poll of directors of programs in pediatric infectious diseases.

Authors:  P E Klass; J O Klein
Journal:  Pediatr Infect Dis J       Date:  1992-09       Impact factor: 2.129

8.  Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.

Authors:  T Q Tan; G E Schutze; E O Mason; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

9.  Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group.

Authors:  E R Wald; S L Kaplan; E O Mason; D Sabo; L Ross; M Arditi; B L Wiedermann; W Barson; K S Kim; R Yogov
Journal:  Pediatrics       Date:  1995-01       Impact factor: 7.124

10.  Therapy of bacterial sepsis and meningitis in infants and children: 1989 poll of directors of programs in pediatric infectious diseases.

Authors:  B M Word; J O Klein
Journal:  Pediatr Infect Dis J       Date:  1989-09       Impact factor: 2.129

View more
  1 in total

1.  Response to 'Benefits of glucocorticoids in the treatment of bacterial meningitis in children: End of the controversy?'.

Authors:  James D Kellner
Journal:  Paediatr Child Health       Date:  2006-01       Impact factor: 2.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.